

**SLC8A1 Antibody (Center) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP8939c****Specification****SLC8A1 Antibody (Center) Blocking Peptide - Product Information**Primary Accession [P32418](#)**SLC8A1 Antibody (Center) Blocking Peptide - Additional Information****Gene ID** 6546**Other Names**Sodium/calcium exchanger 1,  
Na(+)/Ca(2+)-exchange protein 1, Solute  
carrier family 8 member 1, SLC8A1, CNC,  
NCX1**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP8939c](/products/AP8939c) was selected from the Center region of human SLC8A1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**SLC8A1 Antibody (Center) Blocking Peptide - Protein Information****Name** SLC8A1**SLC8A1 Antibody (Center) Blocking Peptide - Background**

In cardiac myocytes, Ca(2+) concentrations alternate between high levels during contraction and low levels during relaxation. The increase in Ca(2+) concentration during contraction is primarily due to release of Ca(2+) from intracellular stores. However, some Ca(2+) also enters the cell through the sarcolemma (plasma membrane). During relaxation, Ca(2+) is sequestered within the intracellular stores. To prevent overloading of intracellular stores, the Ca(2+) that entered across the sarcolemma must be extruded from the cell. The Na(+)-Ca(2+) exchanger is the primary mechanism by which the Ca(2+) is extruded from the cell during relaxation. In the heart, the exchanger may play a key role in digitalis action. The exchanger is the dominant mechanism in returning the cardiac myocyte to its resting state following excitation.

**SLC8A1 Antibody (Center) Blocking Peptide - References**

Palty,R., et.al., Proc. Natl. Acad. Sci. U.S.A. 107 (1), 436-441 (2010) Kepp,K., et.al., BMC Med. Genet. 11, 15 (2010)

**Function**

Mediates the exchange of one  $\text{Ca}(2+)$  ion against three to four  $\text{Na}(+)$  ions across the cell membrane, and thereby contributes to the regulation of cytoplasmic  $\text{Ca}(2+)$  levels and  $\text{Ca}(2+)$ -dependent cellular processes (PubMed:<a href="http://www.uniprot.org/citations/1374913" target="\_blank">1374913</a>, PubMed:<a href="http://www.uniprot.org/citations/11241183" target="\_blank">11241183</a>, PubMed:<a href="http://www.uniprot.org/citations/1476165" target="\_blank">1476165</a>). Contributes to  $\text{Ca}(2+)$  transport during excitation-contraction coupling in muscle. In a first phase, voltage-gated channels mediate the rapid increase of cytoplasmic  $\text{Ca}(2+)$  levels due to release of  $\text{Ca}(2+)$  stores from the endoplasmic reticulum. SLC8A1 mediates the export of  $\text{Ca}(2+)$  from the cell during the next phase, so that cytoplasmic  $\text{Ca}(2+)$  levels rapidly return to baseline. Required for normal embryonic heart development and the onset of heart contractions.

**Cellular Location**

Cell membrane; Multi-pass membrane protein

**Tissue Location**

Detected primarily in heart and at lower levels in brain (PubMed:1374913). Expressed in cardiac sarcolemma, brain, kidney, liver, pancreas, skeletal muscle, placenta and lung (PubMed:1476165)

**SLC8A1 Antibody (Center) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)